Skyrizi — Medical Mutual

Initial criteria

• Patient is age ≥ 18 years
• The medication is prescribed by or in consultation with a rheumatologist or a dermatologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient meets at least one of the following: a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline; OR b) Compared with baseline, patient experienced an improvement in at least one symptom such as less joint pain, morning stiffness, improved function, or decreased soft tissue swelling

Approval duration

initial 6 months, reauth 1 year